icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
AL-034 (or TQ-A3334), a Selective Toll-like Receptor 7 Agonist for Oral Treatment of Chronic Hepatitis B Virus Infection
 
 
  Reported by Jules Levin'
AASLD, Washington DC, USA, October 20-24 2017
 
  AASLD: Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-56136379, a Novel HBV Capsid Assembly Modulator, in Non-cirrhotic, Treatment-naïve Patients with Chronic Hepatitis B. - (11/01/17)
 
An De Creus1, Tine Thoné1, Thierry Verbinnen1, Dorien Verstappen1, Christel Van den Eynde1, Tom Vervoort1, Zhengxian Gu2, Qiong Zhou2, Fei Sun2, Ya Sun2, Charles Z. Ding2, Xiquan Zhang3, Ling Yang3, Xin Tian3, Hongjiang Xu3, Frederik Pauwels1, Leonid Beigelman4, John Fry4, Tse-I Lin4 1Janssen Research & Development, Beerse, Belgium; 2WuXi AppTec, Shanghai, China; 3Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Nanjing, China; 4Alios Biopharma, San Francisco, CA, USA

1205171

1205172

1205173

1205173

1205174

1205174

1205175

1205176